



August 1, 2025

Company: Ono Pharmaceutical Co., Ltd.
Representative: Toichi Takino
Representative Director, President and COO
(Securities Code: 4528 Prime market, TSE)
Contact: Ryuta Imura
Senior Director, Corporate Communications
(Phone: +81-6-6263-5670)

**Notice concerning the Establishment of Ono Global Reinsurance, Inc.
as an Overseas Subsidiary (Specified Subsidiary)**

Osaka, Japan, August 1, 2025 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “ONO”) announced that it resolved to establish Ono Global Reinsurance, Inc. as a wholly-owned subsidiary at the meeting of its Board of Directors held today.

1. Purpose for establishment:

In order to improve risk management systems, ONO will establish Ono Global Reinsurance, Inc., a subsidiary that underwrites non-life insurance of ONO and its group companies as reinsurance, for the purpose of establishing and operating stable insurance programs.

2. Outline of Ono Global Reinsurance, Inc.:

Name	Ono Global Reinsurance, Inc.
Location	State of Hawaii, USA
Representative	Masaki Itoh, Managing Director
Establishment	December 2025 (planned)
Capital	JPY 10 billion (planned)
Business	Reinsurance underwriting for ONO and its group companies
Relationship	A wholly-owned subsidiary of ONO

3. Future outlook

Any impact of this matter on ONO’s business results for the current fiscal year will be marginal. Should there be any events to be disclosed in the future, we will announce them in a timely manner.